AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins
AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.
How this was made
The 30-second read
Why it matters
The company lowered full-year revenue and sharply reduced adjusted EBITDA guidance, attributing the change to margin pressure from a West Coast capitated contract transition and a manufacturer price increase, alongside discontinued-operations accounting effects.
Market read
Traders should focus on the magnitude of the EBITDA guidance reset, the stated cost drivers, and the near-term cash flow deterioration versus prior year.
What to watch
The company expects to eliminate about half of Diabetes Health-related corporate overhead within 12 months, and it also announced restructuring savings and a $235M sale that could improve future continuing-ops cash generation.
Background
AdaptHealth is a healthcare-at-home provider operating under capitated agreements and is narrowing its portfolio, including a planned sale of its Diabetes Health business.
Ticker impact
AdaptHealth cut 2026 adjusted EBITDA guidance from $680-$730M to $490-$520M citing West Coast capitated contract and manufacturer price increase.
Near-term downside bias as investors reprice 2026 profitability and FCF after the guidance cut.
The article provides specific, quantified guidance reductions and attributes them to identifiable cost drivers, plus reports negative YTD FCF and a large goodwill write-down.
Market effects
Signals margin sensitivity in healthcare-at-home capitated models, especially during contract scale-up and supplier pricing changes.
West Coast capitated contract transition is a specific driver, implying regional contract execution risk.
Limited direct global spillover, but it reinforces cost and margin risks in US value-based care delivery models.
Counterpoint
The guidance cut may be partly mechanical from reclassifying Diabetes Health as discontinued and from one-time transition complexity, while organic revenue growth remains strong.
Key entities
- companyAdaptHealth Corp.
Cut 2026 outlook, reported Q2 results, and agreed to sell Diabetes Health for $235M while restructuring and refinancing.
- partnerHumana OneHome
Signed a capitated agreement with AdaptHealth covering South Florida and Texas and involved member transitions.
